Genia Technologies has landed a $5.3 NIH grant to advance its genome sequencing technology. The company will use the money in its work with partners at Columbia University and Harvard Medical school to fund more development of NanoTag, its nanopore-based DNA sequencing platform. Genia CEO Stefan Roever told FierceBiotech Research that the goal is to take his technology from the research lab and put it in the hands of patients in order to sequence a wide variety of diseases. Story